For more information

Contact:

Ericka R. Patrick, RN
341 Ponce de Leon Avenue
Atlanta, GA 30308
404.616.6313

Study Treatment:
Subjects will be randomized in a 2 : 1 ratio to one of the two treatment arms

Arm 1: Elvitegravir 150mg/Cobicistat
150mg/Emtricitabine 200mg/Tenofovir
Alafenamide 10mg (E/C/F/TAF) STR
plus DRV 800mg once daily. Study medication will be provided for Arm 1

Arm 2: Subjects will remain on current, pre-existing ARV regimen

Study Purpose:
The purpose of this study is to evaluate safety and to determine whether
E/C/F/TAF STR plus Darunavir (DRV) is effective against HIV-1 in subjects on
current antiretroviral regimens (ARV) in virologically suppressed, HIV-1 positive subjects

Key requirements to be eligible for the study:

• 48 weeks on study
• ≥ 4mo suppressed on ARVs containing either DRV once a day or twice a day
• Have history of genotype resistance to at least three classes of ARV agents
• Are currently receiving Raltegravir, Elvitegravir, or Dolutegravir (50mg once
daily only)
• Have HIV RNA <50 copies/mL